Evidence map›Paper›PMID 29410301›Full record

Trial reportBiology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation2018

Phase 1/2 Trial of Carfilzomib Plus High-Dose Melphalan Preparative Regimen for Salvage Autologous Hematopoietic Cell Transplantation Followed by Maintenance Carfilzomib in Patients with Relapsed/Refractory Multiple Myeloma.

Luciano J Costa, Heather J Landau, Saurabh Chhabra, Parameswaran Hari, Racquel Innis-Shelton, Kelly N Godby, Mehdi Hamadani, Roni Tamari, Kate Anderton, Pamela Dixon and 1 more

Registry-linked trialOpen access · hybridAbstract readClinical Trial, Phase IClinical Trial, Phase II
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01690143 (Phase 1/2A Study Carfilzomib + High Dose Melphalan as Preparative Regimen for Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma), which is not on this map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.6field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01690143 phase1 / phase2completednot on this map

Phase 1/2A Study Carfilzomib + High Dose Melphalan as Preparative Regimen for Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma

TypeinterventionalSponsorUniversity of Alabama at BirminghamRan2012 to 2017Enrolled45ConditionsMultiple MyelomaArmsCarfilzomib, Melphalan
3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 21 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Trial
  4. Optimizing high dose melphalan.Blood reviews · 2024
    Review
  5. Article
  6. Article
  7. Review
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 5 institutions in 1 country.

Luciano J CostaDepartment of Medicine, University of Alabama at Birmingham, Birmingham, Alabama. Electronic address: ljcosta@uabmc.edu.
Heather J LandauDepartment of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.
Saurabh ChhabraDepartment of Medicine, Medical University of South Carolina, Charleston, South Carolina.
Parameswaran HariDivision of Hematology and Oncology, Medical College of Wisconsin, Milwaukee, Wisconsin.
Racquel Innis-SheltonDepartment of Medicine, University of Alabama at Birmingham, Birmingham, Alabama.
Kelly N GodbyDepartment of Medicine, University of Alabama at Birmingham, Birmingham, Alabama.
Mehdi HamadaniDivision of Hematology and Oncology, Medical College of Wisconsin, Milwaukee, Wisconsin.
Roni TamariDepartment of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.
Kate AndertonHollings Cancer Center, Charleston, South Carolina.
Pamela DixonUniversity of Alabama at Birmingham Comprehensive Cancer Center, Birmingham, Alabama.
Sergio A GiraltDepartment of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.
University of Alabama at Birmingham · USMemorial Sloan Kettering Cancer Center · USMedical College of Wisconsin · USMedical University of South Carolina · USMUSC Hollings Cancer Center · US

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4M
South Carolina Clinical & Translational Research Institute (SCTR)UL1TR001450 · NCATS · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI BRADY, KATHLEEN T., FLUME, PATRICK A · 2015 to 2024
$41.1M
NCATS NIH HHS UL1 TR001450NCI NIH HHS P30 CA008748
6 · The paper itself

Abstract

We performed a phase 1/2 trial to investigate the safety and activity of the second-generation proteasome inhibitor Carfilzomib (K) on days -3/-2 in combination with melphalan 200 mg/m

Indexed as

AgedAntineoplastic Agents, AlkylatingFemaleHematopoietic Stem Cell TransplantationHumansMaleMelphalanMiddle AgedMultiple MyelomaOligopeptidesSalvage TherapyTransplantation, AutologousTransplantation ConditioningAntineoplastic Agents, AlkylatingcarfilzomibMelphalanOligopeptidesAutologous transplantationCarfilzomibMelphalanMultiple myelomaPeripheral blood stem cell transplantation

Identifiers

PMID29410301
PMCPMC7590532
OpenAlexW2786981465

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.